"My patients are definitely having trouble now that the whole world has decided what you and I have always known: that hormones are wonderful for us
In this context, numerous Chinese biopharmaceutical innovators are actively advancing their pipelines in the oral small-molecule GLP-1 space, achieving several high-profile licensing deals: In November 2023, Chengyi Bio licensed its oral small-molecule GLP-1 receptor agonist, ECC5004, to AstraZeneca with a potential deal value of up to $2.01 billion
doi:10.1016/S0140-6736(21)00213-0
In these experiments, ischemic colitis therapy was administered once at early ligation time (IC rats) or alternatively at the early post-ligation time (IC + RL rats)
That doesnt necessarily mean everyone should pursue it
Thus, the rising geriatric population prone to diabetes across Asia Pacific would propel the demand for effective treatments such as GLP-1 analogues during the forecast period